Thieler Law Corp, member of the Investor Attorney Network, is investigating whether members of the board of directors of Achillion Pharmaceuticals Inc (NASDAQ: ACHN) acted responsibly on behalf of investors’ profitability in the planned sale to Alexion Pharmaceuticals Inc (NASDAQ: ALXN).

On October 16, 2019, Achillion Pharmaceuticals Inc (NASDAQ: ACHN) and Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) announced that they had entered into a merger agreement. Under the terms of the merger agreement, Alexion will offer Achillion shareholders $6.30 per share in cash for all outstanding shares.    

Based in Blue Bell, Pennsylvania, and founded in 1998 Achillion Pharmaceuticals Inc discovers, develops, and commercializes small molecule drug therapies for immune system disorders.

The investigation is looking to uncover whether Achillion Pharmaceuticals Inc was undervalued at the cost of the shareholders considering one analyst’s opinion of their stock is valued at $11.00 per share.

If you purchased Achillion Pharmaceuticals Inc (NASDAQ: ACHN) prior to October 16, 2019, you should contact Thieler Law Corp at mail@thielerlaw.com or call +1 (619) 377 - 4324.

Thieler Law Corp purchases advertisements on search engines, social media sites and other websites. If you send us information, note that does not create an attorney-client relationship with the firm. Materials are provided for informational purposes only and do not constitute legal advice. We are only licensed to practice law in Germany. We are neither licensed nor qualified to render advice on US Federal or State law.

Thieler Law Corp

2534 State Street - Suite 406,

San Diego, CA 92101

by

email: mail@thielerlaw.com 

or

telephone at +1 (619) 377 - 4324

or

visit our website http://www.thielerlaw.com/ 

or

Facsimile: +1 (619) 785 – 3185